
AxoGen, Inc.
AXGN
Updated: 24/09/2026, 10:09:45
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
No summaries found.
- Share price
- $43.32
- Market cap
- $2.33B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Michael D. Dale
- Employees
- 622
- IPO date
- 17/12/1986
- Beta
- 1.163
- Last dividend
- $0.00
- Day range
- $43.25 – $44.84
- 52-week range
- $15.27 – $52.91
- 1-day performance
- -2.74%
- 1-year performance
- 183.69%
- Current drawdown (1Y)
- -18.13%
- CIK
- 0000805928
- CUSIP
- 05463X106
- ISIN
- US05463X1063
- Created
- 07/12/2025, 02:53:23
- Last update
- 24/09/2026, 10:09:45
Track AxoGen, Inc. with an AI analyst
See which prediction-market events move AXGN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
MarketBeat • STOCK • 14/05/2026, 13:07:07
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha • STOCK • 13/05/2026, 20:00:46
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 28/04/2026, 19:41:31
AxoGen (AXGN) Q1 Earnings Lag Estimates
Zacks Investment Research • STOCK • 28/04/2026, 11:16:41
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
Zacks Investment Research • STOCK • 17/04/2026, 10:00:56
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
GlobeNewsWire • STOCK • 14/04/2026, 09:00:00
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
The Motley Fool • STOCK • 21/03/2026, 20:53:29
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Seeking Alpha • STOCK • 06/03/2026, 12:15:55
Axogen Q4: EPS Miss Amid Biologics Transition
Seeking Alpha • STOCK • 25/02/2026, 06:23:33
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
GlobeNewsWire • STOCK • 17/02/2026, 08:00:00